Community Update: LEMBAZ™ (adrabetadex) Is Approved
Dear NPC Community,
I am so pleased to finally share with you all that today, the U.S. Food and Drug Administration (FDA) approved LEMBAZ™ (adrabetadex). Many of you have waited years for this news, and we want to take a moment to recognize what it means for you and your family, as well as all of the patients and families who contributed to its journey, without whom this milestone would not have been possible.
LEMBAZ is approved for children and adults with Niemann-Pick disease type C (NPC) whose neurological symptoms began before the age of 6. It is the first FDA approved medicine to address the underlying cholesterol trafficking defect that causes NPC and the first medicine to improve survival in infantile-onset NPC.
This approval belongs to this community. It reflects nearly two decades of determination from families, caregivers, clinicians, researchers, and advocates. You shared your stories, you took part in the research and the Expanded Access Program, and you kept showing up through years of uncertainty.
LEMBAZ will be available at commercial treatment sites nationwide in early December. If your child is in the Expanded Access Program, a Beren Family Access Manager can begin helping you plan the transition to commercial treatment immediately, even before LEMBAZ is available at those sites.
We know that approval alone is not enough. A medicine can only help if people can get it, and our goal is to ensure that every patient who can benefit from LEMBAZ has access to it. Over many years, families have told us what that takes in real life: someone to call, help with the paperwork, a treatment site within reach, and other families who understand.
In our last update, we told you we were building support for families. With approval, that work becomes LEMBAZ Family Support, a program designed to give every family one-on-one help from a dedicated Beren team throughout the treatment journey.
LEMBAZ Family Support is live right now. This is how it works:
- One person to call. Every family will have a dedicated Beren Family Access Manager, who serves as a single point of contact. Your Family Access Manager will work with you to find a treatment site, ideally close to home, and to coordinate access to treatment. You should not have to work through this alone.
- Navigation support. Family Access Managers help coordinate insurance coverage, travel, and the other practical parts of treatment, so that families can start and stay on therapy and focus on what matters most. Eligible families receive full out-of-pocket assistance, so there is no out-of-pocket cost.
We have heard from many families considering treatment that it would be invaluable for them to be able to connect with someone else who has experienced it. And so, we have launched a Caregiver Ambassador Program for families who are considering LEMBAZ to talk with caregivers who have firsthand experience with treatment, ask their questions, and hear what to expect. Sometimes the best answers come from another family.
Please reach out with any question, large or small. You can call the LEMBAZ Family Support team at 1-844-237-3600, Monday to Friday, 8 am to 8 pm ET, email LembazFamilySupport@berentx.com, or visit LembazRx.com.
I want to acknowledge that we know that not every family who needs treatment falls within today’s approved indication. Our work for families whose neurological symptoms began at age 6 or later continues, and we will keep you informed along the way.
A note on safety. Please read the full Prescribing Information, including the Boxed WARNING, and the Important Safety Information below, and talk with your care team about whether LEMBAZ is right for you or your child.
It is an honor to share this day with you. From all of us at Beren, thank you for your trust, your partnership, and your persistence. We know that today may bring joy, relief, grief, and many questions, sometimes all at once. We are here for all of it, and we will keep listening.
With gratitude,
Jason Camm
Chief Executive Officer
Beren Therapeutics P.B.C.
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION
LEMBAZ™ (adrabetadex) is a prescription medicine used to reduce the risk of death in adults and children who weigh 7 kg (about 15 pounds) or more and have Niemann-Pick disease type C (NPC) with neurological symptoms that began before 6 years of age.
IMPORTANT SAFETY INFORMATION
WARNING: HEARING IMPAIRMENT INCLUDING PERMANENT HEARING LOSS
Treatment with LEMBAZ has resulted in permanent hearing impairment.
- Before you or your child starts LEMBAZ, your healthcare provider will do a complete hearing evaluation (audiology evaluation) to establish baseline hearing levels. This includes tests such as pure tone audiometry, speech recognition, and tympanometry.
- During treatment, your healthcare provider will use the results of these hearing evaluations to decide how to adjust the LEMBAZ dose.
- To decide the next dosage level, the hearing evaluation will be repeated 1 to 2 weeks after the first dose at each dosage level, and again 1 to 2 weeks after the second dose at each dosage level. Each evaluation is done before the next dose.
- If the dosage level stays the same for 2 doses in a row, or the maximum dose is reached, hearing evaluations will be done once a month until 3 stable results in a row are obtained. After that, they will be repeated every 12 months.
Hearing impairment, including permanent hearing loss: LEMBAZ can cause hearing impairment. People treated with LEMBAZ have had permanent hearing impairment that ranged from mild to profound hearing loss, including some people whose hearing was normal before treatment. It is not known whether continuing or lowering the dose affects the risk of further hearing loss. Your healthcare provider will not increase the dose if hearing tests show hearing impairment beyond set limits.
Ataxia: LEMBAZ can cause ataxia (problems with balance and coordination). Ataxia can include falls, unsteady walking or poor coordination, dizziness, and low muscle tone (hypotonia). This may occur shortly after a dose, typically in the first few days. Severe ataxia requiring hospitalization has occurred. Ataxia may be more severe at higher doses. Your healthcare provider may lower the dose if these effects are severe.
Fatigue: LEMBAZ can cause fatigue, including weakness, feeling unwell, and sleepiness. This may occur shortly after a dose, typically in the first few days. Severe fatigue requiring hospitalization has occurred. Fatigue may be more severe at higher doses. Your healthcare provider may lower the dose if these effects are severe.
Most common side effects: The most common side effects (reported in 25% or more of patients in a clinical trial) were hearing impairment, ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.
These are not all the possible side effects of LEMBAZ. Call your healthcare provider for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Mandos LLC at 1-844-237-3600.
LEMBAZ is for intrathecal use only (injected into the fluid around the spinal cord).
Please see full Prescribing Information, including Boxed WARNING, for LEMBAZ.
This information does not replace talking with your healthcare provider.